Fuld + Company

Fuld + Company

Category: Content
Type: Blog Article

Generated 6 days ago

New blog articles detected

  • Strategies for Investing in Developing Markets

    The global economy is in transition, not so much as the result of fluctuating superpower politics, but more so as the quiet byproduct of shifting investment in emerging economies. We are at the end of supersized returns previously found in Brazil, Russia, India, China, and South Africa (BRICS), foreign direct investment constants since 2001 that have in recent years become increasingly...

Fuld + Company

Category: Content
Type: Blog Article

Generated 2 weeks ago

New blog articles detected

  • The Importance of Brand Awareness in the Pharmaceutical Industry

    Today’s reality for pharmaceutical companies is anything but care free. Competition from the generics market continues to rise, the FDA’s approvals of new drugs has declined, and resolution of the debate surrounding the Affordable Care Act is uncertain. Additionally, the new administration has called for pricing restraints. This is certainly enough to cause angst among the most experie...

Fuld + Company

Category: Content
Type: Blog Article

Generated 4 weeks ago

New blog articles detected

  • Competitive Chess with Cheese

    There’s a savage war going on at your local deli counter. Shelf space at America’s deli counters is the newest casualty of a cutthroat retail brand battle in today’s supermarkets. Deeply entrenched and beloved brands like Boar’s Head and Land O’Lakes are silently duking it out in a fight over who reigns supreme in the deli section. The result to the winner is likely to be increased rev...

Fuld + Company

Category: Content
Type: Blog Article

Generated 1 month ago

New blog articles detected

  • Quality Drug Data Not a Guarantee of Future Revenue

    On March 16, 2017, Amgen released positive cardiovascular outcomes data for its PCSK9 inhibitor, Repatha. Yet, it could be tough going to receive wide coverage of the drug from managed care companies due to concerns over high cost and availability of efficacious, economical alternatives. Positive outcomes data alone will not sway payers if the cost-benefit ratio is too high, especially...

Fuld + Company

Category: Content
Type: Blog Article

Generated 1 month ago

Fuld + Company

Category: Content
Type: Blog Article

Generated 2 months ago

Fuld + Company

Category: Content
Type: Blog Article

Generated 4 months ago

New blog articles detected

  • Fake News and Competitive Strategy

    The diagnostic industry provides essential information for healthcare, and is driven by medical technology, the aging population, and the complexity of disease. One sector, the global blood testing market, in 2015 was valued at $51.5 billion and is expected to grow to $62.9 billion by 2024. Understanding how to craft strategy in this market is critical, given the funding required for n...

Fuld + Company

Category: Content
Type: Blog Article

Generated 5 months ago

New blog articles detected

  • New Year's Resolutions for the Competitive Strategist

    As 2016 ends, few would argue that most businesses are in for a roller coaster ride in 2017.  The United States is set for a hard-right turn politically, the Brexit process is facing new uncertainties regarding its duration and manner, and accusations of Russian cyber espionage and China’s muscle-flexing in the Asia Pacific region foreshadow turbulence in international relations. Longe...

Fuld + Company

Category: Content
Type: Blog Article

Generated 5 months ago

New blog articles detected

  • The Ever Shifting Pharmaceutical Marketplace – Biosimilars and Interchangeability

    The FDA recently approved Amjevita (adalimumab-atto), Amgen’s adalimumab biosimilar product for seven inflammatory indications in adult patients1. It was the fourth biosimilar approved by the FDA, and was announced just days after approval was granted for Sandoz’s Erelzi (etanercept-szzs), an Enbrel® biosimilar. Both Enbrel® and Humira® are blockbuster drugs with worldwide revenues ove...

Fuld + Company

Category: Content
Type: Blog Article

Generated 5 months ago

New blog articles detected

  • Strategies for Surving an Industry Downturn

    In late October, GE announced that it is spinning off its oil and gas business and merging it with Baker Hughes, embarking on a strategy of convergence, expanding its offerings and therefore the potential revenue it can generate, to remain vibrant and viable in the current industry downturn. In 2014, GE Oil and Gas developed a business plan based on oil prices of approximately $100 per...

Fuld + Company

Category: Content
Type: Blog Article

Generated 5 months ago

Fuld + Company

Category: Content
Type: Blog Article

Generated 6 months ago

New blog articles detected

  • Qualitative Methods Enrich Quantitative Data

    Co-Written by Ola Jachtorowicz Seventy-six percent of millennials want to drive an eco-friendly car. Ninety-two percent of students prefer physical books to e-readers. Ninety percent of senior executives confirm that customer experience is one of their top three priorities. Sixty-seven percent of U.S. manufacturing executives plan to increase investments in data analytics next year. ...

  • Strategy for When Satisfied Customers Don’t Come Back

    A month ago, my wife and I celebrated our third wedding anniversary. As we celebrated, I thought back to the autumn of 2007 when we first met. I was a single 20-something professional, less than a year removed from active duty in the Marine Corps and anticipating settling down and starting a family. Having tried the “bar scene” to no avail, I decided to join eHarmony. Six months later...

  • Upcoming Event: Ken Sawka Speaking at BU Questrom Health & Life Sciences Conference October 14th

    On Friday, October 14th, Fuld + Company CEO, Ken Sawka, is speaking at the Boston University Questrom School of Business's fourth annual Health & Life Sciences Conference.  The Health & Life Sciences Conference is an annual, student-organized event that brings together a diverse audience of more than 350 students and professionals across all sectors of the US healthcare industry for v...

  • Social Media Has Changed the Trajectory of Corporate Scandals

    There is an old rule of thumb that for every letter a congressman receives, there are 50 people thinking the same thing who didn’t pick up a pen. For every customer who bothers to complain, 26 others remain silent (and buy your competitor’s product instead). How many people does a Facebook comment represent? What about a like or a share?

Fuld + Company

Category: Content
Type: Blog Article

Generated 8 months ago

Fuld + Company

Category: Positioning & Presence
Type: Page Design Update

Generated 9 months ago

Fuld + Company

Category: Positioning & Presence
Type: Page Design Update

Generated 9 months ago

Fuld + Company

Category: Positioning & Presence
Type: Page Design Update

Generated 9 months ago

Fuld + Company

Category: Positioning & Presence
Type: Page Design Update

Generated 9 months ago

Fuld + Company

Category: Positioning & Presence
Type: Page Design Update

Generated 9 months ago

Fuld + Company

Category: Positioning & Presence
Type: Page Design Update

Generated 9 months ago

Fuld + Company

Category: Content
Type: Blog Article

Generated 9 months ago

Fuld + Company

Category: Content
Type: Blog Article

Generated 10 months ago

Out-Market Your Competitors?

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in